AU2019363840B2 - Pyrrolo(2,3-d)pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto - Google Patents

Pyrrolo(2,3-d)pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto Download PDF

Info

Publication number
AU2019363840B2
AU2019363840B2 AU2019363840A AU2019363840A AU2019363840B2 AU 2019363840 B2 AU2019363840 B2 AU 2019363840B2 AU 2019363840 A AU2019363840 A AU 2019363840A AU 2019363840 A AU2019363840 A AU 2019363840A AU 2019363840 B2 AU2019363840 B2 AU 2019363840B2
Authority
AU
Australia
Prior art keywords
pyrrolo
pyrimidin
prop
amino
methylpiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019363840A
Other languages
English (en)
Other versions
AU2019363840A1 (en
Inventor
Douglas James Critcher
David Sydney Bernard Daniels
Kevin Paul Girard
Gregory Scott Goeken
Peter Robert Rose
Brian Matthew Samas
Yong Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU2019363840A1 publication Critical patent/AU2019363840A1/en
Application granted granted Critical
Publication of AU2019363840B2 publication Critical patent/AU2019363840B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019363840A 2018-10-22 2019-10-21 Pyrrolo(2,3-d)pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto Active AU2019363840B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748628P 2018-10-22 2018-10-22
US62/748,628 2018-10-22
PCT/IB2019/058940 WO2020084435A1 (en) 2018-10-22 2019-10-21 Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto

Publications (2)

Publication Number Publication Date
AU2019363840A1 AU2019363840A1 (en) 2021-04-01
AU2019363840B2 true AU2019363840B2 (en) 2021-12-09

Family

ID=68343187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019363840A Active AU2019363840B2 (en) 2018-10-22 2019-10-21 Pyrrolo(2,3-d)pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto

Country Status (15)

Country Link
US (1) US12116368B2 (https=)
EP (1) EP3870584A1 (https=)
JP (1) JP6944496B2 (https=)
KR (1) KR102629132B1 (https=)
CN (1) CN112888691B (https=)
AR (1) AR116797A1 (https=)
AU (1) AU2019363840B2 (https=)
BR (1) BR112021007568A2 (https=)
CA (1) CA3059000C (https=)
IL (1) IL282446B2 (https=)
MX (1) MX2021003241A (https=)
SG (1) SG11202103667QA (https=)
TW (1) TWI729530B (https=)
WO (1) WO2020084435A1 (https=)
ZA (1) ZA202101735B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020338043B2 (en) 2019-08-26 2025-12-18 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors
KR20220123271A (ko) * 2019-12-31 2022-09-06 화이자 알앤디 유케이 리미티드 1-((2S,5R)-5-((7H-피롤로[2,3-d]피리미딘-4-일)아미노)-2-메틸피페리딘-1-일)프로프-2-엔-1-온의 안정한 즉시 방출형 정제 및 캡슐 제형
CN113121539A (zh) * 2019-12-31 2021-07-16 江苏艾立康医药科技有限公司 一种pf06651600的制备方法
CN111732591B (zh) * 2020-06-15 2022-06-10 江苏艾立康医药科技有限公司 Pf-06651600 l-酒石酸盐，晶型及其制备方法
CN111620880B (zh) * 2020-06-15 2022-06-10 江苏艾立康医药科技有限公司 Pf-06651600 dl-酒石酸盐，晶型及其制备方法
CN114835715B (zh) * 2020-06-15 2024-04-05 江苏艾立康医药科技有限公司 Pf-06651600马来酸盐及其制备方法
WO2022012587A1 (zh) * 2020-07-14 2022-01-20 苏州晶云药物科技股份有限公司 丙烯酮类化合物的丙二酸盐晶型及其制备方法
KR102473645B1 (ko) * 2020-08-28 2022-12-05 (주)부흥산업사 (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법
CN112877379B (zh) * 2021-01-18 2023-09-01 华南理工大学 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法
WO2025144783A1 (en) * 2023-12-28 2025-07-03 Aclaris Therapeutics, Inc. Methods of synthesizing substituted pyrrolopyrimidine compounds
WO2025146702A1 (en) * 2024-01-03 2025-07-10 Msn Laboratories Private Limited, R&D Center Solid state forms of 1-{(2s,5r)-2-methyl-5-[(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino] piperidine-1-yl}prop-2-en-1-one 4-methylbenzene-1-sulfonic acid
WO2025219875A1 (en) * 2024-04-17 2025-10-23 Alembic Pharmaceuticals Limited Solid forms of ritlecitinib or its salts
CN118420493B (zh) * 2024-04-24 2026-04-14 山东福长药业有限公司 一种2,5-二取代氨基己酸酯的制备方法及使用其制备利特昔替尼的方法
WO2025244944A1 (en) * 2024-05-20 2025-11-27 Opna Bio SA Crystal forms of an agent
WO2025257773A1 (en) 2024-06-11 2025-12-18 Assia Chemical Industries Ltd. Processes for the preparation of ritlecitinib and intermediates thereof
CN119060059B (zh) * 2024-08-21 2025-10-28 武汉九州钰民医药科技有限公司 一种甲苯磺酸利特昔替尼的制备工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318565A1 (en) * 2013-12-05 2018-05-09 Pfizer Inc Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911365A (pt) 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN105859721B (zh) * 2015-01-22 2018-04-17 浙江京新药业股份有限公司 一种伊布鲁替尼的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3318565A1 (en) * 2013-12-05 2018-05-09 Pfizer Inc Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

Also Published As

Publication number Publication date
CA3059000A1 (en) 2020-04-22
US20210387989A1 (en) 2021-12-16
SG11202103667QA (en) 2021-05-28
TWI729530B (zh) 2021-06-01
EP3870584A1 (en) 2021-09-01
AR116797A1 (es) 2021-06-16
AU2019363840A1 (en) 2021-04-01
ZA202101735B (en) 2022-07-27
JP6944496B2 (ja) 2021-10-06
KR20210080468A (ko) 2021-06-30
US12116368B2 (en) 2024-10-15
BR112021007568A2 (pt) 2021-07-27
KR102629132B1 (ko) 2024-01-29
TW202033525A (zh) 2020-09-16
CN112888691A (zh) 2021-06-01
MX2021003241A (es) 2021-05-12
IL282446B1 (en) 2024-02-01
JP2020066629A (ja) 2020-04-30
WO2020084435A1 (en) 2020-04-30
IL282446B2 (en) 2024-06-01
IL282446A (en) 2021-06-30
CA3059000C (en) 2026-04-14
CN112888691B (zh) 2023-10-31

Similar Documents

Publication Publication Date Title
AU2019363840B2 (en) Pyrrolo(2,3-d)pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
CA2916605C (en) Solid forms of a macrocyclic kinase inhibitor
EP3687535B1 (en) Crystalline hydrochloride salt of lumateperone
AU2021332886A1 (en) Salt of rho-associated protein kinase inhibitor, solid form of the salt, preparation method for same, and uses thereof
CA3167093A1 (en) Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
WO2011108689A1 (ja) ピラゾロピリミジン誘導体
EP4545531A1 (en) Tricyclic compounds and uses thereof
CN110950847B (zh) 氘代azd9291化合物的新晶型及其用途
TWI820301B (zh) 結晶型嘧啶基－３，８－二氮雜雙環〔３．２．１〕辛烷基甲酮化合物及其用途
US20250270221A1 (en) Solid forms of jak inhibitor and process of preparing the same
RU2849555C2 (ru) Тозилат пирроло[2,3-d]пиримидина, его кристаллическая форма и способ получения и промежуточные продукты для этой цели
HK40054619B (zh) 吡咯并[2，3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体
HK40054619A (en) Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
TWI873326B (zh) (1R,3R)-3-(氰甲基)-3-(4-(6-(1-甲基-1H-吡唑-4-基)吡唑并[1,5-a]吡-4-基)-1H-吡唑-1-基)環丁烷-1-甲腈之結晶型及其製備方法與用途
TW202508560A (zh) 製備ｐ１３ｋ抑制劑之方法
HK40120276A (en) Tricyclic compounds and uses thereof
HK40120533A (zh) Btk抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)